Female Sexual Dysfunction - Pipeline Review, H1 2023
Female Sexual Dysfunction - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2018, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 5, 2 and 1 respectively.
Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Callitas Therapeutics Inc
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
GlaxoSmithKline Plc
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Palatin Technologies Inc
Pivot Pharmaceuticals Inc
Re-Pharm Ltd
S1 Biopharma Inc
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Callitas Therapeutics Inc
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
GlaxoSmithKline Plc
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Palatin Technologies Inc
Pivot Pharmaceuticals Inc
Re-Pharm Ltd
S1 Biopharma Inc
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PVT-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-3006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Estrogen Receptor for Female Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
May 09, 2018: AMAG Pharmaceuticals Commends CMS for Clarifying Part D Coverage of Treatments for Moderate to Severe Dyspareunia Due to Menopause
Apr 05, 2018: Acerus to Present TEFINA at the Next CHINABIO Partnering Forum
Mar 26, 2018: AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials
Jan 09, 2018: Emotional Brain's FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials
Jan 08, 2018: Callitas Health Provides Update on Extrinsa
Oct 11, 2017: Callitas Announces Positive FDA Response to Extrinsa Pre-IND Submission
Jul 24, 2017: AMAG Pharmaceuticals Launches Intrarosa (prasterone) in the U.S. - a Novel Product to Treat Moderate to Severe Dyspareunia Due to Menopause
Jul 18, 2017: M Pharmaceutical Plans to Submit Extrinsa PIND Meeting Request Letter and Package to US FDA
Jul 14, 2017: M Pharmaceutical Provides Update on Extrinsa
Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction
Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women’s Sexual Health Annual Meeting
Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerList of Tables
Number of Products under Development for Female Sexual Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H1 2018
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H1 2018
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2018
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H1 2018
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2018
Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H1 2018
Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2018
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2018
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H1 2018
Female Sexual Dysfunction - Pipeline by Pivot Pharmaceuticals Inc, H1 2018
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2018
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H1 2018
Female Sexual Dysfunction - Dormant Projects, H1 2018
Female Sexual Dysfunction - Dormant Projects, H1 2018 (Contd..1), H1 2018
Female Sexual Dysfunction - Discontinued Products, H1 2018List of Figures
Number of Products under Development for Female Sexual Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Research Methodology
The research study released with title "Female Sexual Dysfunction - Pipeline Review, H1 2023" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Female Sexual Dysfunction Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Female Sexual Dysfunction Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Female Sexual Dysfunction Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Female Sexual Dysfunction Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Female Sexual Dysfunction - Pipeline Review, H1 2023" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
